# An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)

> **NCT03157167** · PHASE1 · COMPLETED · sponsor: **Navidea Biopharmaceuticals** · enrollment: 15 (actual)

## Conditions studied

- Kaposi Sarcoma
- HIV Infections

## Interventions

- **DRUG:** Tc99m-tilmanocept

## Key facts

- **NCT ID:** NCT03157167
- **Lead sponsor:** Navidea Biopharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-01
- **Primary completion:** 2019-11-05
- **Final completion:** 2020-03-30
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-03-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03157167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03157167, "An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03157167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*